1

Bluechiip Limited (ASX: BCT)Investor Update - March 2012

For

per

sona

l use

onl

y

2

Disclaimer

Material used in this presentation is summary of available information, and while given in good faith, is professional opinion only. Any investor in Bluechiip Limited (BCT) should refer to all BCT ASX releases and statutory reports before considering investment in company.

Certain information may have been derived from third parties and though BCT has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by BCT.

Any forward-looking statements in this presentation involve subjective judgement and analysis and are subject to uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT. Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guarantee in relation to this presentation.

BCT reserves right to update, amend or supplement information in this presentation at any time in its absolute discretion without incurring any obligation to do so.F

or p

erso

nal u

se o

nly

3

Company summary

Strong IP position - 15 patents, 5 granted in USA and Europe

1st generation commercial product to be available 2H 2012 - tooling up to commence volume production with manufacturing partners

Securing agreements with global commercial/strategic partners for development and distribution

Securing first commercial sales

Platform technology with multiple market applications - market pull in initial market of biobanking and biorepositories where opportunity to become best practice/”the standard” in cryogenic storage

Experienced board and management - commercially and globally focussed

Increasing interest in BCT by investment markets - expect coverage as reach value inflection points

Innovative technology company ready to launch product in coming months

For

per

sona

l use

onl

y

4

Corporate summary

Total - 359; Top 20 - 58.8M shares (72.8%)Shareholders

~2.1M (2.6%)/~6.8M (8.4%) including OMT’sTrades since listing

$0.10 to $0.30Trading range

ASX code/Industry group BCT (Technology Hardware & Equipment)

Market capitalization $17.8M (@ $0.22/share) (recent range $18-20M)

Shares issued 80.9M (24.7M under escrow (30.5%) till 9 June 2013 - founders, directors, major shareholders); Free float - 56.2M/69.5%

Unlisted options issued 27.4M (employees, directors, pre-IPO shareholders, IPO applicants -$0.20 Aug/Sep 2012 and Aug 2013, $0.30 Dec 2012) (16.0M under escrow to Aug 2013)

Announcements/AGM 10/11/11IPO

9/6/11$0.25

$0.22

For

per

sona

l use

onl

y

5

Board & management

International expert/key-opinion-leader (KOL) in biobanking; over 20 years experience in industry; consultant to Bluechiip since November 2010

Lisa MirandaSenior Advisor –Business Development

Over 5 years with Bluechiip; actively involved in MEMS technology for over 10 years

Dr Jason ChaffeyCTO

MANAGEMENT

Over 20 years experience in pharmaceuticals industry; involved with BCT since July 2007; CEO of Immuron

Joe BainiNon Executive

Co-founder; over 20 years experience in chartered accounting and consulting prior to founding Zmood Innovations (technology consultancy) in 2001 and Bluechiip in 2003

Brett SchwarzMD & CEO

Substantial investor/shareholder; over 35 years experience with healthcare and other companies; Chairman/Director of 3 other ASX listed companies

Iain KirkwoodNon Executive Chairman

BOARD

For

per

sona

l use

onl

y

6

IP portfolio

• All IP wholly owned by company

• Patents• Portfolio of 15 patents over 7 patent families

• 5 granted in USA and Europe

• Some patent applications currently under examination and awaiting examiners report

• Progress patent applications from Provisional PCT National Phase over coming year

• Continue to build portfolio by filing new patent applications for further protection

• Established Freedom-to-Operate (FTO)

• Trade marks• Trade marks (word and logo) registered in Australia and USAFor

per

sona

l use

onl

y

7

Global focus & presence

Head officeMelbourne, Australia

STMicroelectronicsChip/tag fabrication

Italy

Manufacture ofreader hardware

Malaysia

BusinessDevelopment office

Massachusetts, USA(Lisa Miranda)

UK/Europe officeProduct development

London, UK(Dr Ian Johnston)

Primarymarket focus

USA

For

per

sona

l use

onl

y

8

What is bluechiip®?

• System-based platform technology solution• Chip/tag - attached to sample storage container

(vial/tube, bag, box, cassette, rack/frame/tower)• Reader hardware• Software

• Provide chain-of-custody tracking and reporting• Tag – electronic license plate (unique ID)

with sensing capabilities• Based on MEMS technology – purely mechanical

device - no electronics• Survives and operates in extreme temperature

conditions (+60°C to -196°C)• Can sense and record temperature history• Frost resistant • Secure and difficult to clone• Easily molded into consumables• Immune to gamma radiation (used for sterilization)

• System solution – much more than just the tag!

For

per

sona

l use

onl

y

9

Manufacturing and development partners

• Chip/tag - engaged with STMicroelectronics

• Vials/tubes - discussion with leading vial/tube manufacturers including Corning (as announced in November 2011) and others

• Bags - discussion with major bag manufacturers

• Equipment - discussion with major suppliers of -80ºC mechanical and -196ºC/LN2 freezers and accessories (racks)

• Reader hardware – process of selecting contract manufacturer

• Software – in-house

For

per

sona

l use

onl

y

10

What problem does bluechiip® solvein initial market application?

• Existing labeling and tracking methodologies have disadvantages in cryostorage environment where there are now a growing number of samples being managed

• Labels (hand-written/pre-printed)• Labels fall off• Transcription errors• Can’t sense temperature

• Barcodes (linear/2D)• Need line of site• Can’t been read where frost exists• Can’t sense temperature

• RFID• Can’t survive plastic injection molding process• Can’t survive high temperatures of sterilization and gamma irradiation• Can’t survive AND operate in low temperatures down to LN2/-196ºC• Can’t sense temperature with separate device

• Traditional techniques (labels and barcodes) lead to manual processes where errors can be made and quality of sample being stored is at risk of being contravened and/or lost

For

per

sona

l use

onl

y

11

Current storage environment -where is that sample?

For

per

sona

l use

onl

y

12

Real world cases

US woman receives $1M compensation for IVF error -Aug 2004

Errors at IVF clinics 'almost double' in 12 monthsHundreds of failures in fertility treatment include lost embryos and sperm mix-ups - Apr 2010Errors at fertility clinics almost doubled in 12 months, it was reported today. Number of mistakes at IVF centres in England and Wales rose from 182 in 2007/8 to 334 in 2008/9. Blunders included embryos being lost or implanted in wrong woman, and eggs being fertilised with wrong man's sperm.

IVF clinic blunders treble in three years as ten mistakes every week bring heartbreak to couples - Aug 2011

Someone else's baby: An inconceivable error of IVF - Feb 2011

California couple sue IVF doctor over ‘lost’ embryos –Aug 2011

Mislabeled units of umbilical cord blood detected by quality assurance program at transplantation center - Jun 2009

IVF blunders destroy baby dreams of 100 Victorian patients - Jul 2009 - Melbourne Herald-SunSwan Hill couple told of their pain at not being able to have another baby after clinic lost husband's frozen sperm. Couple paid storage fee for three years, but clinic had no record of where their gift of life had gone when they wanted to have another baby. After investigating clinic found five unmarked vials at bottom of storage freezer but, because they could not guarantee whose sperm it was, they had to be destroyed.

WIRED (June 2010) - Libraries of Flesh: The Sorry State of Human Tissue Storage• Many biobank managers didn’t seem to know exactly what was in their own freezers. Some specimens had never been checked before they were put in storage and turned out to be unfit for analysis. • One bank at major university claimed to have more than 12,000 samples of glioblastoma in its collection. Only 18 of those were good enough to use. Rate of unacceptable shipments from other institutions ran as high as 99 percent. • …..inability to obtain high-quality biosamples is growing problem in labs, eating away at progress in medicine ……One in five confessed that inferior quality of samples might be compromising their data.

For

per

sona

l use

onl

y

13

Benefits of adoptingbluechiip® tracking solution

Improves operating efficiency, thus throughputOpportunity to generate additional revenue as greater capacity (reduce waiting lists), ability to win tenders, etcEnhances sample securityMaintains integrity of sample - read sample data while stored within low-temperatures Reduces sample handling and breakageSingle tag tracks both ID and temperatureSimplifies and speeds up sample retrievalReduces legal exposure, cost of insuranceImproves operator safety (OH&S)

Today’s environment is all aboutethical accountability, risk management, regulation, financial viability and quality assurance to customers

For

per

sona

l use

onl

y

14

How big is initial market opportunity?

• bluechiip® suited to applications where:• Labor intensive• Higher sample value• Longer storage life• Samples stored in low temps (-80°C to -196°C)

• 1-2B biospecimens stored around world and growing at 100-200M samples p.a.

• Driven by favorable political and scientific environment, enhanced government funding and greater public awareness and support

• Areas of growth• Regenerative and molecular medicine/stem cells – driven by storage of

umbilical cord blood and stem cell research for new therapies• Cell lines• Compound management• IVF• Clinical trials • Cryopreservation and biostorage• Laboratory and sample management• Clinical trials

For

per

sona

l use

onl

y

15

How big is initial market opportunity?

• Biobanking market• Estimated sales of US biobank resources and services $7.9B in 2009

growing to $44.6B by 2025 (Source: Biobanking for Medical R&D: Technology and Market 2010-2025 by visiongain)

• Global biobanks market to reach US$22.3B (Source: Biobanks: A Global Strategic Business Report

by Global Industry Analysts) - driven by favorable political and scientific environment, enhanced government funding and greater public awareness and support

• Stem cell market• US market expected to grow @ CAGR of 84% during 2009-2012 to reach

~US$889M by 2012 (Source: US Stem Cell Market Analysis report by RNCOS)

• Driven by storage of umbilical cord blood and stem cell research for new therapies

• IVF market• Over 1M IVF stimulations globally p.a.• Increasing number of IVF cycles and samples being stored

• Cryopreservation• Growth of cryopreservation how track samples in low temperatures

And there are many other market applications within and outside of healthcare/life sciences that will be pursued

For

per

sona

l use

onl

y

16

How intend to get bluechiip®

into hands of market?

• Get bluechiip® to end-users/customers:• Biobanks• Clinical research organizations (CRO’s) – clinical trials• Cord blood, stem cell, cell lines• IVF and cell therapy facilities• Pharmaceutical and biotech companies• Other

by working with global distribution and channel partners who are already supplying end-users/customers:

• Suppliers of lab consumables (vials, etc) and their own distributors• Suppliers of lab equipment (mechanical/LN2 freezers) and their own

distributors• Software providers• System integrators• Service providers• OthersFor

per

sona

l use

onl

y

17

Recent developments withcustomers and commercial partners

• Agreements secured with major US organizations - path to sales and commercial partnerships #1 – ATCC (American Type Culture Collection)

• World-leading biological materials resource and standards organization• Executed Collaborative Evaluation and Pilot Agreement - announced 8

November 2011• Pilot trial recently performed

#2 - Leading biorepository and biobanking services provider• Executed Collaborative Evaluation and Pilot Agreement in September 2011• Pilot trial recently performed

#3 – Corning/Corning Life Sciences• Major consumables supplier• Executed Collaborative Evaluation and Pilot Agreement - announced 11

November 2011• Involved in ATCC pilot trial recently performed

• Numerous other interested parties

For

per

sona

l use

onl

y

18

The future of tracking is bluechiip®

“Has it been bluechiiped?”

© bluechiip ® bluechiip and bluechiip (Logo) are registered trade marks of Bluechiip Ltd 18

For

per

sona

l use

onl

y